In vitro diagnostic regulation

In vitro diagnostic regulation refers to the legal framework governing IVDs, including design, manufacture, and monitoring. According to EU IVDR 2017/746 and Taiwan's Medical Device Act Article 26, IVDs must be classified by risk (Class A to D) and undergo conformity assessment. This ensures safety and accuracy, preventing misdiagnosis. Companies must be closely aligned with ISO 13485 and ISO 14971 standards to manage risks throughout the product lifecycle, from R&D to post-market surveillance. Failure to comply can lead to product recalls, heavy fines, and damage to corporate reputation.

Implementation typically follows three stages: Risk Classification (per EU IVDR Annex VIII), Quality Management System Establishment (ISO 13485), and Post-Market Surveillance (PMS). For example, a Taiwan-based IVD manufacturer implemented ISO 14971 risk management and EU IVDR compliance within 12 months, reducing product-related complaints by 35% and increasing EU market share by 20%. This systematic approach ensures that risks are identified, mitigated, and documented, which is critical for both patient safety and business continuity.

Taiwan enterprises face three primary challenges: first, the transition from the old IVD Directive to EU IVDR requires much more extensive clinical evidence, which many SMEs lack. Second, the complexity of technical documentation often leads to delays in notified body reviews. Third, the cost of compliance can be significant. To overcome these, companies should prioritize digitalizing their quality documentation, investing in clinical data-gathering capabilities, and seeking specialized consultants like Winners Consulting to navigate the regulatory landscape efficiently.

Winners Consulting Services Co., Ltd. specializes in In vitro diagnostic regulation for Taiwan enterprises, delivering compliant management systems within 90 days. We have assisted over 100 companies in achieving EU IVDR and ISO 13485 compliance. Free consultation: https://winners.com.tw/contact